drugset / Trial / NCT04723472
Bismuth Quadruple Therapy With Cefuroxime for Helicobacter Pylori Eradication Treatment
RandomizedParallel-groupOpen-labelTreatment
Summary
To observe the efficacy of cefuroxime-containing bismuth quadruple regimen in the eradication treatment of Helicobacter pylori, and to evaluate whether it can be used as a remedial treatment for Helicobacter pylori after initial or repeated treatment failure.
Timeline
- Start
- 2023-08-01
- Primary completion
- 2025-12-31
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cefuroxime | Small molecule | 500 mg | Oral |
| Subject | Tetracycline | Unknown | 500 mg | Oral |
| Background | Metronidazole | Small molecule | 400 mg | Oral |
| Background | Rabeprazole | Small molecule | 20 mg | Oral |
| Background | colloidal bismuth pectin | Unknown | 200 mg | Oral |